Dysregulation of glutamine/glutamate metabolism in COVID‐19 patients: A metabolism study in African population and mini meta‐analysis

Abstract

Coronavirus disease 2019 (COVID‐19) remains a serious global threat. The metabolic analysis had been successfully applied in the efforts to uncover the pathological mechanisms and biomarkers of disease severity. Here we performed a quasi‐targeted metabolomic analysis on 56 COVID‐19 patients from Sierra Leone in western Africa, revealing the metabolomic profiles and the association with disease severity, which was confirmed by the targeted metabolomic analysis of 19 pairs of COVID‐19 patients. A meta‐analysis was performed on published metabolic data of COVID‐19 to verify our findings. Of the 596 identified metabolites, 58 showed significant differences between severe and non‐severe groups. The pathway enrichment of these differential metabolites revealed glutamine and glutamate metabolism as the most significant metabolic pathway (Impact=0.5; ‐Log10P=1.959). Further targeted metabolic analysis revealed six metabolites with significant inter‐group differences, with glutamine/glutamate ratio significantly associated with severe disease, negatively correlated with 10 clinical parameters and positively correlated with SPO 2 (r s =0.442, P=0.005). Mini meta‐analysis indicated elevated glutamate was related to increased risk of COVID‐19 infection (pooled OR=2.02; 95% CI: 1.17–3.50) and severe COVID‐19 (pooled OR=2.28; 95% CI: 1.14–4.56). In contrast, elevated glutamine related to decreased risk of infection and severe COVID‐19, the pooled OR were 0.30 (95% CI: 0.20–0.44), and 0.44 (95% CI: 0.19–0.98), respectively. Glutamine and glutamate metabolism are associated with COVID‐19 severity in multiple populations, which might confer potential therapeutic target of COVID‐19, especially for severe patients. This article is protected by copyright. All rights reserved.

Metabolomics as a powerful tool for diagnostic, pronostic and drug intervention analysis in COVID-19

“…This metabolic signature seems to be rather homogeneous worldwide, with equivalent results obtained when considering very distant geographical and cultural regions such as Mexico ( López-Hernández et al, 2021 ), Italy ( Saccon et al, 2021 ; Ghini et al, 2022b ; Ciccarelli et al, 2022 ), and Africa ( Li X. et al, 2022 ). Instead, characteristic but distinct metabotypes can be associated to pregnant women ( Id et al, 2022 ), newborn ( Kontou et al, 2021 ) and infantile ( Wang et al, 2021 ) COVID-19 population.…”

Serum nuclear magnetic resonance metabolomics analysis of human metastatic colorectal cancer: Biomarkers and pathway analysis

“…As expected, the mean GGR value obtained for cancer samples (0.28 ± 0.09) was significantly higher ( p < 0.05) than for control samples (0.17 ± 0.02). However, we must be cautious, because GGR is already described as a characteristic ratio for some diseases, as coronary artery disease, schizophrenia, and even in COVID‐19 52–54 …”

Systematic Mendelian randomization study of the effect of gut microbiome and plasma metabolome on severe COVID-19

“…A key physiological function of alanine is to transport pyruvate and glutamate from the muscles to the liver, a process known as the glucose-alanine cycle. Data from patients with different severity grades of COVID-19 show that circulating pyruvate level is the strongest determinants of severe COVID-19 (55), and a meta-analysis indicates elevated glutamate is associated with an increased risk of COVID-19 severity(56).…”